BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 10, 2006
View Archived Issues
Medicure Acquires Marketed CV Drug Aggrastat From MGI
As a complement to its lead cardiovascular drug, MC-1, Medicure Inc. acquired rights to its first marketed product, Aggrastat, a glycoprotein IIb/IIIa inhibitor to treat acute coronary syndrome. (BioWorld Today)
Read More
HGS Outlines LymphoStat-B's Phase III Plan; Riquent Returns
Read More
CpGs Tweak Cells Toward Innate, Adaptive Immunity
Read More
Altor Moving To Clinic With T-Cell Receptor-Based Drug
Read More
Clinic Roundup
Read More
Other News To Note
Read More